Astrazeneca plc, of London, reported top-line results from RECLAIM-1 and RECLAIM-2, the pivotal phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections (cIAIs).